GIP(1-42)

DRUG4 trials

Sponsors

University Hospital, Gentofte, Copenhagen, University of Copenhagen

Conditions

BloodpressureGlucose MetabolismGlucose Metabolism DisordersIncretin Effect

Unknown Phase

GIP Receptor Antagonist Studies in Humans

CompletedNCT02747472

University Hospital, Gentofte, CopenhagenGlucose Metabolism

Start: 2016-04-30End: 2016-07-31Updated: 2017-04-27

Physiology of GIP(1-30)NH2 in Humans

CompletedNCT04792762

University Hospital, Gentofte, CopenhagenGlucose Metabolism Disorders

Start: 2018-06-12End: 2019-06-09Updated: 2021-03-11

The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function

RecruitingNCT06194955

University of CopenhagenIncretin Effect

Start: 2023-01-04End: 2027-12-31Target: 60Updated: 2024-05-07

Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals

RecruitingNCT06934473

University Hospital, Gentofte, CopenhagenBloodpressure

Start: 2025-05-21End: 2026-01-31Target: 16Updated: 2025-09-08

Related Papers

GIP(3-30)NH<sub>2</sub> is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.

2017-09-2565 citations